Medartis Holding AG (MED) AI Stock Analysis

• Market Cap: CHF1.09B
• Dividend Yield: N/A
• Average Volume (3M): 6.62K
• Price to Earnings (P/E): 282.8
• Beta (1Y): 1.02
• Revenue Growth: 7.29%
• EPS Growth: -112.70%
• Country: CH
• Employees: 816
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 13,618,142
• 10 Day Avg. Volume: 6,931
• 30 Day Avg. Volume: 6,617
• PEG Ratio: 0.44
• Price to Book (P/B): 2.60
• Price to Sales (P/S): 3.12
• P/FCF Ratio: 33.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF89.00
• Price Target Upside: 11.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 57 Neutral
• Price Target: CHF88.00 ▲(9.86% Upside)

The overall stock score is primarily influenced by strong financial performance, particularly in revenue growth and cash flow improvement. However, technical analysis indicates bearish momentum, and the valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield. These factors combined suggest a cautious outlook for the stock.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust demand for Medartis' products and effective market penetration, supporting long-term business expansion.

Cash Flow Improvement

Significant improvement in free cash flow enhances Medartis' ability to invest in growth opportunities and maintain financial flexibility.

Balance Sheet Health

A strong balance sheet with low leverage ensures Medartis can withstand economic downturns and invest in strategic initiatives.

Negative Factors

Low Net Profit Margin

Low net profit margins suggest challenges in cost management, potentially impacting profitability and limiting reinvestment capacity.

Modest Return on Equity

A modest ROE indicates inefficiencies in generating returns from equity, which could affect investor confidence and future capital raising.

Operational Efficiency

Moderate operational margins highlight the need for improved efficiency to enhance profitability and competitive positioning.

Medartis Holding AG Business Overview & Revenue Model

Company Description

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Medartis generates revenue primarily through the sale of its orthopedic and neurosurgical implants and instruments. Key revenue streams include direct sales of surgical products to hospitals and clinics, as well as distribution agreements with medical device partners. The company benefits from ongoing partnerships with healthcare providers and organizations that facilitate the adoption of its products in surgical procedures. Additionally, Medartis invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. The company's focus on high-quality, specialized medical solutions allows it to command premium pricing, further contributing to its financial performance.

Medartis Holding AG Financial Statement Overview

Summary

Medartis Holding AG shows strong revenue growth and financial stability with a robust gross profit margin and improved cash flow. However, low net profit margins and modest return on equity indicate room for operational improvements.

Income Statement

Medartis Holding AG demonstrates a strong revenue growth trajectory with a 6% increase from 2023 to 2024. The gross profit margin has remained robust at approximately 79.5% in 2024. However, the net profit margin remains relatively low at 1.57%, indicating potential challenges in cost management or operational efficiency. The EBIT and EBITDA margins are moderate at 3.5% and 13.4% respectively, showing room for improvement in operational leverage.

Balance Sheet

The company maintains a healthy balance sheet with a favorable equity ratio of 58.6% in 2024, indicating a strong capital structure. The debt-to-equity ratio is at a manageable 0.45, reflecting prudent financial leverage. Return on equity is modest at 1.31%, suggesting potential underutilization of shareholder funds. Overall, the financial position is stable with potential for enhanced returns.

Cash Flow

Medartis Holding AG exhibits a significant improvement in free cash flow, growing from CHF 1.17 million in 2023 to CHF 21 million in 2024. The operating cash flow to net income ratio is strong, highlighting efficient cash conversion from profits. The free cash flow to net income ratio is robust at 5.95, underscoring efficient capital management. However, consistent positive cash flow generation remains critical for sustained financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	236.34M	224.83M	212.01M	182.82M	159.88M	127.65M
Gross Profit	186.96M	178.68M	167.57M	135.39M	121.57M	93.89M
EBITDA	35.38M	30.18M	24.69M	15.64M	26.10M	13.96M
Net Income	-487.00K	3.53M	619.00K	-5.78M	6.84M	-943.57K
Balance Sheet
Total Assets	465.70M	459.96M	349.53M	327.89M	298.18M	282.79M
Cash, Cash Equivalents and Short-Term Investments	120.51M	138.69M	25.20M	20.60M	82.64M	82.73M
Total Debt	123.88M	121.23M	42.17M	52.04M	24.07M	27.18M
Total Liabilities	204.50M	190.31M	94.58M	90.11M	74.18M	69.76M
Stockholders Equity	261.21M	269.65M	254.96M	237.78M	224.00M	213.04M
Cash Flow
Free Cash Flow	19.47M	21.00M	5.05M	-22.72M	10.57M	-455.29K
Operating Cash Flow	27.49M	28.17M	19.96M	-3.93M	20.95M	12.61M
Investing Cash Flow	-24.29M	-19.06M	-37.83M	-52.91M	-15.87M	-22.86M
Financing Cash Flow	-7.70M	100.58M	23.21M	-3.90M	-4.78M	-4.73M

Medartis Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 80.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Negative. The current price of 80.1 is below the 20-day moving average (MA) of 85.86, below the 50-day MA of 86.27, and above the 200-day MA of 77.15, indicating a neutral trend. The MACD of -1.68 indicates Positive momentum. The RSI at 31.24 is Neutral, neither overbought nor oversold. The STOCH value of 11.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MED.

Medartis Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOON	73 Outperform	CHF12.58B	24.10	―	2.02%	6.58%	-10.02%
MOVE	73 Outperform	CHF2.98B	33.23	23.83%	0.47%	16.59%	65.76%
SFZN	70 Outperform	$3.54B	22.30	15.79%	0.48%	0.77%	16.70%
BSLN	68 Neutral	CHF595.63M	8.05	―	―	58.51%	―
TECN	67 Neutral	$1.86B	29.21	4.57%	2.05%	-9.34%	-37.50%
MED	57 Neutral	CHF1.09B	282.78	―	―	7.29%	-112.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medartis Holding AG Corporate Events

Medartis to Present 2025 Half-Year Results via Webcast

Medartis Holding AG has announced a webcast presentation of its half-year results for 2025, scheduled for August 19, 2025. The event will feature presentations by CEO Matthias Schupp and CFO Dirk Kirsten, and will be available for viewing via MS Teams. This announcement signifies Medartis’s commitment to transparency and engagement with stakeholders, providing insights into its financial performance and strategic direction.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.

Medartis Completes Acquisition of KeriMedical to Bolster Hand Surgery Portfolio

Medartis Holding AG has acquired the remaining 53% of shares in KeriMedical, a company specializing in hand and wrist surgery implants, for CHF 99 million. This acquisition, following the FDA approval of KeriMedical’s TOUCH thumb prosthesis, strengthens Medartis’ position in joint replacement and expands its network of surgeons, with an immediate positive impact on sales growth and EBITDA margin. KeriMedical will continue as an independent brand within Medartis, retaining its development and marketing teams, while co-founders Dougal Bendjaballah and Bernard Prandi remain on the board. The acquisition enhances Medartis’ competencies in hand and wrist surgery, aligning with its strategic goals and expanding its market reach, particularly in Europe, the US, and Australia.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.